BRIEF-Lilly's Jaypirca (Pirtobrutinib) Significantly Reduced The Risk Of Disease Progression Or Death By 45% When Added To A Venetoclax Time-Limited Regimen In People With Previously Treated Cll/Sll

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00

June 14 (Reuters) - Eli Lilly and Co LLY.N:

  • LILLY'S JAYPIRCA (PIRTOBRUTINIB) SIGNIFICANTLY REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 45% WHEN ADDED TO A VENETOCLAX TIME-LIMITED REGIMEN IN PEOPLE WITH PREVIOUSLY TREATED CLL/SLL

  • ELI LILLY - STUDY MEETS PRIMARY ENDPOINT WITH 45% RISK REDUCTION (HR=0.55; P=0)

Source text: ID:nPnX9TkBa

Further company coverage: LLY.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.